PerspectiveFunding

Financing translation: Analysis of the NCATS rare-diseases portfolio

See allHide authors and affiliations

Science Translational Medicine  25 Feb 2015:
Vol. 7, Issue 276, pp. 276ps3
DOI: 10.1126/scitranslmed.aaa2360

Article Information

vol. 7 no. 276 276ps3

PubMed: 
Print ISSN: 
Online ISSN: 
History: 

    Author Information

    1. David E. Fagnan1,2,*,
    2. N. Nora Yang3,*,
    3. John C. McKew3, and
    4. Andrew W. Lo1,2,4,5,
    1. 1Operations Research Center, Massachusetts Institute of Technology (MIT), Cambridge, MA 02142, USA.
    2. 2Sloan School of Management and Laboratory for Financial Engineering, MIT, Cambridge, MA 02142, USA.
    3. 3National Center for Advancing Translational Sciences, U.S. National Institutes of Health, Rockville, MD 20850, USA.
    4. 4Computer Science and Artificial Intelligence Laboratory and Department of Electrical Engineering and Computer Science, MIT, Cambridge, MA 02139, USA.
    5. 5AlphaSimplex Group, LLC, Cambridge, MA 02142, USA.
    1. Corresponding author. E-mail: alo-admin{at}mit.edu
      • *These authors contributed equally to this work.

      • Present address: aTyr Pharma, 3545 John Hopkins Court, Suite 250, San Diego, CA 92121, USA.

      AltMetrics

      Article usage

      AbstractFullPDF
      Feb 20151298590174
      Mar 201514302140351
      Apr 2015349261114
      May 201519114494
      Jun 2015997659
      Jul 2015555052
      Aug 2015977154
      Sep 201510112971
      Oct 2015669559
      Nov 2015876993
      Dec 2015615494
      Jan 2016535578
      Feb 2016635977
      Mar 20161134574
      Apr 2016655377
      May 2016665198
      Jun 2016915486
      Jul 2016393236
      Aug 2016443444
      Sep 2016494367
      Oct 2016765978
      Nov 2016605950
      Dec 2016533254
      Jan 2017463257
      Feb 201710348116
      Mar 2017656589
      Apr 20172752123
      May 20174660107
      Jun 2017373748
      Jul 2017554171
      Aug 2017685970
      Sep 2017496771
      Oct 2017376677